MedTrace Logo

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01636076 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 629

Last updated 2014-11-17

Study results available
· View outcomes & findings →

Summary

To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with COPD

Conditions

Interventions

DRUG

QMF149

delivered via Concept1 device

DRUG

Salmeterol

delivered via Accuhaler®

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • Australia
  • Belgium
  • Bulgaria
  • Denmark
  • Finland
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Israel
  • Malaysia
  • Poland
  • Romania
  • Singapore
  • South Africa
  • Spain
  • Sweden
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01636076 on ClinicalTrials.gov